中华眼科杂志
中華眼科雜誌
중화안과잡지
Chinese Journal of Ophthalmology
2008年
3期
281-284
,共4页
孙晓东%许薇琦%Philip J.Rosenfeld
孫曉東%許薇琦%Philip J.Rosenfeld
손효동%허미기%Philip J.Rosenfeld
眼疾病%新生血管化,病理性%抗体,单克隆%血管生成抑制剂
眼疾病%新生血管化,病理性%抗體,單剋隆%血管生成抑製劑
안질병%신생혈관화,병이성%항체,단극륭%혈관생성억제제
Eye diseases%Neovascularization,pathologic%Antibodies,monoclonal%Angiogenesis inhibitors
近年来,国外应用Bevacizumab治疗新生血管性眼病取得了良好的效果,受到了眼科界的广泛关注.作为一种效价比较高的药物,Bevacizumab已经被证明不仅具有抗眼部新生血管形成的作用,更能通过降低血管通透性达到抗渗出的效果.因此,有必要就Bevacizumab治疗新生血管性眼病的疗效和安全性进行综述,为玻璃体内注射Bevacizumab治疗新生血管性眼病的科学性、有效性及安全性提供理论依据.(中华眼科杂志,2008,44:281-284)
近年來,國外應用Bevacizumab治療新生血管性眼病取得瞭良好的效果,受到瞭眼科界的廣汎關註.作為一種效價比較高的藥物,Bevacizumab已經被證明不僅具有抗眼部新生血管形成的作用,更能通過降低血管通透性達到抗滲齣的效果.因此,有必要就Bevacizumab治療新生血管性眼病的療效和安全性進行綜述,為玻璃體內註射Bevacizumab治療新生血管性眼病的科學性、有效性及安全性提供理論依據.(中華眼科雜誌,2008,44:281-284)
근년래,국외응용Bevacizumab치료신생혈관성안병취득료량호적효과,수도료안과계적엄범관주.작위일충효개비교고적약물,Bevacizumab이경피증명불부구유항안부신생혈관형성적작용,경능통과강저혈관통투성체도항삼출적효과.인차,유필요취Bevacizumab치료신생혈관성안병적료효화안전성진행종술,위파리체내주사Bevacizumab치료신생혈관성안병적과학성、유효성급안전성제공이론의거.(중화안과잡지,2008,44:281-284)
Clinical trial of off-label use of Bevacizumab for the treatment of neovascular diseases of the eve showed good therapeutic results.It has been demonstrated that this therapy is efficient and safe in the treatment of choroidal neovascularization due to age-related macular degeneration,pathologic myopia and other neovascular eye diseases in short term period.The potential risks to the patients are minimal,and the cost-effectiveness is so obvious that the treatment strategy using intravitreal bevacizumab is logical and understandable.(Chin J Ophthalmol,2008,44:281-284)
